CRABP-II Activators

CRABP-II Activators are a collection of compounds that indirectly enhance the function of Cellular retinoic acid-binding protein 2 (CRABP-II), mainly through modulating the levels and activity of retinoic acid and its related signaling pathways. These activators function by either increasing the availability of retinoic acid, the primary ligand for CRABP-II, or by affecting the metabolic pathways associated with retinoid metabolism. Key examples include All-trans Retinoic Acid (ATRA), Isotretinoin, Acitretin, Tazarotene, Bexarotene, Adapalene, and Fenretinide. These compounds, either as retinoids or retinoid-like substances, elevate retinoic acid levels in the body or are converted into active forms that interact with retinoic acid receptors, thereby enhancing the transport and regulatory functions of CRABP-II.

Additionally, the list includes specific inhibitors like ATRA CYP26 Inhibitors, which prevent the breakdown of retinoic acid, consequently increasing its availability for CRABP-II. Similarly, compounds such as Citral and Disulfiram indirectly boost retinoic acid levels by inhibiting enzymes that metabolize its precursors. This leads to an increase in the precursors of retinoic acid, such as retinaldehyde, thus potentially enhancing CRABP-II activity. Nonsteroidal anti-inflammatory drugs (NSAIDs) like Flufenamic Acid and Diflunisal are also included due to their potential effects on retinoid metabolism, which can indirectly influence CRABP-II's function.